Your SlideShare is downloading. ×
  • Like
Data disclosurein Kyrgyzstan
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Data disclosurein Kyrgyzstan

  • 190 views
Published

Presentation by Suluke Abakirova, National META Secretariat, Kyrgyzstan during the MeTA countries sharing meeting, London 2009.

Presentation by Suluke Abakirova, National META Secretariat, Kyrgyzstan during the MeTA countries sharing meeting, London 2009.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
190
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
1
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA

Transcript

  • 1. Suluke Abakirova National META Secretariat Data Disclosure in Kyrgyzstan MeTA 18/01/10
  • 2. Type of data being collected
    • Medicines Registration and Quality Assurance (existing laws/policies and associated regulations; enforcing (mechanism, authorized bodies); accessibility to information/data/results/; barriers to use)
    • - Market registration procedures and registration status of all medicines
    • - Quality assurance data during registration or procurement (existing laws/policies and associated regulations…)
    • - Routine quality testing and adverse event monitoring (existing laws/policies and associated regulations…)
    • Medicine Promotion
      • Medicines promotion regulations, policies, and industry practices (existing laws/policies and associated regulations…)
    18/01/10 MeTA
  • 3. Type of data being collected
    • Medicine Availability
    • - Standard treatment guidelines
    • - Essential medicines list
    • - Routine audits for public, private, and non-profit medicines
    • outlets
    • Medicine Prices
    • - Public sector medicines procurement prices ( Mandatory health Insurance Fund – price for drugs to be reimbursed within Additional Drug package program, wholesale prices – wholesale distributors through their websites and by request, retail prices – DRA retail prices monitoring on monthly basis)
  • 4. Overview of disclosure process and engagement of stakeholders (Stakeholders involvement)
    • Source of information:
    • - Government sector ( existing laws/policies and associated regulations; procedures – in most cases available through websites or in printed version; but limited access to data/results
    • - Private sector (wholesale prices on
    • medicines posted on the websites/web pages and available on request)
    • - Non-government sector (some data and the results of the surveys: pharmacovigilance (very limited due to ineffective system, access to the medicines for certain groups of patients (bronchial asthma, with mental disorders etc.)
    18/01/10 MeTA
  • 5. Lessons Learned
    • Information/data
    • 1. Available and published (sometimes outdated), or submitted by the request – needs to be updated regularly and to be easily accessible
    • 2. Available, not published, but still accessible by request – needs to be sorted out/classified, analyzed and published/posted on the websites
    • 3. Existing but pigeon-hole - needs to be found out, obtained, revealed, become public
    • 4. Non-existent – needs to be gathered if/when necessary/critical, analyzed, published/posted/accessible
    18/01/10 MeTA
  • 6. Main challenges
    • The information submitted by key respondents within one particular matter could differ between different respondents, unwillingness to speak why the practice differs from that one proposed/stipulated by the current regulations
    • Reluctance to provide some information
    • Needs to be very careful so that information collected will not affect anybody negatively
  • 7. Type of support needed
    • Management of Information systems
    • Techniques and expertise in particular studies to collect the data (i.e., drug quality surveys, drug supply chain, price components, improvement of reimbursement system within Health Insurance system) and interventions (i.e., to raise awareness)
    • Best practices to be shared, adopted and possibly introduced (if appropriate)
    18/01/10 MeTA
  • 8. Thank you!
    • Suluke Abakirova
    • [email_address]
    • 996 (555) 055707
    18/01/10 MeTA